So, you’re an eager founder with the next best thing since sliced bread in your hands and your IP adviser has told you that you must not expose your idea without first securing a Non Disclosure Agreement (NDA). Or maybe, it was another adviser or friend who told you to get an NDA to prevent anyone stealing your idea.
So far, that makes sense and seems like good advice.
Next, you decide to approach Angel investors so that you can ask them to put their hard-earned money into your fledgling business and help turn your great IP into mountains of cash.
That too makes sense and seems a reasonable approach.
Your IP attorney, or your lawyer provide you with the correct documentation — a Non-Disclosure Agreement (NDA) or a Confidentiality Agreement (CA) designed to protect your intellectual property (IP). (One copied from a mate is not a good idea, unless your mate is a specialist lawyer.)
Investors have agreed to meet with you and, to pave the way for a full and frank discussion, you send them your NDA to sign and return prior to the meeting.
Yet, they say no!?!
You’re bewildered and think, ‘Are these guys out to steal my idea? Do they not take seriously the confidentiality of my business? Will they betray my great IP to my competitors? Why are they being so difficult?!?
What is the commercial value of an NDA?
There are two very good reasons for having an NDA:
- To create a paper trail to protect IP prior to getting formal IP protection in place; and,
- As the basis for legal action after damage has resulted from an intentional breach.
The former is most commonly relevant for IP that may be subject to patent protection and, thus, must be withheld from the public domain. The latter is only relevant if it happens and if there are sufficient funds to undertake the expensive, protracted legal battle over an issue that is often harder to prove than it may seem at first glance.
Different investors will have different answers and we won’t try to answer for them all.
We restrict this discussion to Angel investors who are conducting themselves professionally with the intent to invest in a portfolio of early-stage ventures (i.e. the vast majority).
If yours is not such a company, or your prospective investor is not such an investor, then the reality of your situation may be very different to what follows. If you are an inventor and not an entrepreneur then your situation is very different again and what follows may be instructive but, is not the right discussion for you.
The Investor’s Perspective
To build an early-stage investment portfolio an investor will typically have first meetings/conversations with dozens to hundreds of companies a year and invest in no more than a handful at best.
Investors tend to seek opportunities in businesses that they understand. So, they usually see many businesses with very similar ideas for very similar markets. This means that while you think your secret idea is unique, the investor may have already heard the same idea from one or more others.
Ethical business people, including investors, will not sign contracts which they know they cannot honour, or which make unreasonable claims on their own right to operate. An NDA can be such a contract if presented as a precursor to any discussion. To honour the contract the investor must have constant and perfect recall of every little idea and detail she/he has heard from possibly hundreds of discussions on the topic and not to speak those details in the wrong context.
Investors expect the founder to be able to explain the business opportunity including the “secret sauce” without revealing the intimate detail of the “secret sauce”. There are many aspects of the business opportunity for consideration before it is necessary to delve into the intricacies of the protectable IP.
Whether the secret sauce is software (copyright), hardware (patent), branding (trademark), or process (trade secret), it is the outcomes — the effects, the market, the pain to be solved — that is of most initial interest to the investor.
When seeking investment it is the founder’s job to be a salesperson. When selling to a customer one doesn’t have to explain the secret of the product, one only has to explain why the secret delivers a benefit to the customer that the customer values. If the founder can’t have that conversation with an investor then he/she probably is not yet ready for investment.
Does the investor want to trust a founder who must tell her/his secret at the very first meeting? Does that inspire confidence in the business acumen of the founder? Probably not.
Once an investor is engaged and serious about considering an investment then it is normal to make a formal agreement on confidentiality. For example, confidentiality is a standard term in a terms sheet. If the investor doesn’t use that process then he/she may well be ready to sign a suitable NDA, one that has clearly defined coverage, lasts for no more than twelve months maximum (usually six months is more reasonable) and limits the liability for the investor to a reasonable claim for damages due to intentional breach.
A good investor will often require that the NDA be two way but, more on that below.
From the investor’s perspective, the detail of the IP is either unimportant (as it often is at first contact), so there is no need for the NDA, or the detail of the IP is of critical importance (as it often is once serious interest in the investment opportunity has arisen) so the NDA is a natural alignment of interests.
The Founder’s Perspective
The founder has worked hard and long to develop something he/she sees as unique and of commercial value. Some initial advice from an IP expert has reinforced the belief that, subject to proper scrutiny and description, the IP is protectable. At that point, all too often, the founder needs someone else’s money to pay for the IP protection.
Thus, we come to the apparent catch-22 of having a secret that you mustn’t share yet, is the basis for convincing an investor to support the business. This is a misconception!
Investors rarely invest in the secret IP and usually invest in the commercial opportunity to sell a business based on the IP. Investors want a return, not to steal an idea, not to cheat a founder and not to be difficult to work with in a business.
To raise investment capital a founder will typically have dozens of meetings with prospective investors over a period of anything from six months to six years. The initial goal of contacts with investors should be to engage them in the market opportunity, in the vision for a solution and in the credibility of the person/team to execute/realise the success of that solution.
None of that requires disclosure of how the secret detail of the solution works.
As mentioned above, when seeking investment it is the founder’s job to be a salesperson. A sale is a process and the first step in that process is not to demand exclusivity. Exclusivity is either bought or earned and, in the case of raising capital, it is usually earned. An NDA implies exclusivity and that brings with it constraints on both parties. Would you ask a date to sign a pre-nuptial agreement before the first date?
Most of these NDA are one way, designed to protect the founders IP. Will those founders sign a two way NDA, one which protects the investor’s IP and prevents the founder from using any of the investor’s suggestions, comments, or observations without prior license from the investor to do so?
Will the founder’s legal advisers counsel them to sign such an NDA? Can the founder afford to negotiate such an NDA with every prospective investor before knowing if the investor is interested or capable of investing?
From the founder’s perspective, there must be more to the business opportunity than the core IP and there must be a story about how to build value in the business that leverages the IP.
The Reality
An advisor who tells you to stay away from investors who don’t sign your NDA before the first conversation is giving bad advice. Life is not that simple.
Make sure the advisor has the commercial knowledge, as well as the legal knowledge, to be giving commercial advice.
If not, get a good commercial advisor to complement the IP advisor. Whether one advisor or two, the advice should guide the founder on disclosure and strategy so that it is possible to have several, ever deeper conversations with a prospective investor before invoking the need for an NDA.
Protecting IP is in the common interests of the founder and the investor.
Melbourne Angels and other Angel groups typically give a best effort undertaking of confidentiality for information submitted to them. Many VC firms provide similar assurances.
The commercial acumen to conduct business without betraying company secrets is an essential quality for any businessperson. There is a time and a place for an NDA and that is once both parties have established sufficient mutual interest to know it is worth their time to delve into the deeper mysteries of the protectable IP.
Hi Jordan, I’m a designer based in Melbourne. I’m interested in working towards submitting the necessary details sufficient to attract an investment. Over the last few years I have designed a small wearable medical device to assist someone who suffers a range of mental health conditions, the device and the associative methods act as a means of self managed early intervention to alleviate any adverse symptoms in conditions like anxiety and panic.
Currently the only means to treat these and similar conditions is with pharmaceutical products (generally antidepressant drugs) and psychotherapy (Cognitive Behavioral Therapy)
I’m looking to prepare a patent application to protect any intercultural property, as you would be aware; there are prescribed aspects in respect of confidentiality in the Australian patent process that prohibit any release of material that may for the basis of a patent application unless it is in confidence (usually in the form of a NDA or similar)
If I’m reading your comments correctly as detailed on your web site your group will not formally sign an NDA initially, until your group wishes to engage in a preliminary meeting with the founder where they may indicate a willingness to proceed to a further meeting, and from there sign an NDA where further details of the elements making up the confidentiality can be revealed.
If this interpretation is correct; my understanding is that I should proceed and prepare a presentation without any mention of the confidential elements with the understanding your group may requested them at some point in the future where the relevant parties may sign a suitable NDA and possibly proceed with a further meeting.
Is it possible to comment on my understandings to enable a suitable application to be prepared. Regards Graeme Riordan
Hi Graeme,
In essence you are correct. It should be more than enough for you to describe what your device will do and why that will be commercially effective without having to tell us how the device does whatever is novel. In other words, you can tell us what is the novel benefit of your design without disclosing the novel detail.
In practice we never sign an NDA, once we get to the level of interest that warrants due diligence you and we both sign a terms sheet which includes provisions for mutual confidentiality.
I will note that we don’t fund concepts, we’d expect that a fundable medical device company already has a working prototype that can evidence the efficacy and potential of the product.
I hope this helps you decide how to proceed.
Regards, Jordan